/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Smoking Cessation is an emerging landscape with 23 programs across 21 companies. 7 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
95%
Small molecule
20 of 21 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 96% of 23 pipeline programs.
Analysis
383
clinical trials
Clinical Trials
383 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)